139 related articles for article (PubMed ID: 11747323)
41. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
42. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Dunn BK; Ford LG
Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
[TBL] [Abstract][Full Text] [Related]
43. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
[TBL] [Abstract][Full Text] [Related]
44. [From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].
Kreienberg R; Kafka A
MMW Fortschr Med; 2003 Jun; 145(24):32-3. PubMed ID: 12866296
[No Abstract] [Full Text] [Related]
45. Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3.
Duschek EJ; Gooren LJ; Netelenbos C
Maturitas; 2005 Jul; 51(3):286-93. PubMed ID: 15978972
[TBL] [Abstract][Full Text] [Related]
46. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
47. The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women.
dos Santos LG; da Silva BB
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):165-7. PubMed ID: 21741149
[TBL] [Abstract][Full Text] [Related]
48. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
Birzniece V; Sutanto S; Ho KK
J Clin Endocrinol Metab; 2012 Apr; 97(4):E521-7. PubMed ID: 22319035
[TBL] [Abstract][Full Text] [Related]
49. Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.
Schairer C; Hill D; Sturgeon SR; Fears T; Pollak M; Mies C; Ziegler RG; Hoover RN; Sherman ME
Int J Cancer; 2004 Feb; 108(5):773-9. PubMed ID: 14696106
[TBL] [Abstract][Full Text] [Related]
50. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
[TBL] [Abstract][Full Text] [Related]
51. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial.
Signori C; DuBrock C; Richie JP; Prokopczyk B; Demers LM; Hamilton C; Hartman TJ; Liao J; El-Bayoumy K; Manni A
Eur J Clin Nutr; 2012 Aug; 66(8):878-84. PubMed ID: 22669332
[TBL] [Abstract][Full Text] [Related]
52. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
[TBL] [Abstract][Full Text] [Related]
53. Effects of raloxifene on serum macrophage colony-stimulating factor and interleukin-18 levels in postmenopausal women younger than 60 years.
Oztas E; Kurtay G
Menopause; 2010; 17(6):1188-93. PubMed ID: 20613670
[TBL] [Abstract][Full Text] [Related]
54. [A case of lung and pleural metastases from breast cancer responding to toremifene].
Inoue K; Tabei T; Kusawake T; Sugamata N; Suemasu K; Higashi Y; Kurosumi M
Gan To Kagaku Ryoho; 2001 Feb; 28(2):221-4. PubMed ID: 11242650
[TBL] [Abstract][Full Text] [Related]
55. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
Canobbio L; Cannata D; Miglietta L; Boccardo F
Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
[TBL] [Abstract][Full Text] [Related]
56. [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)].
Shiba E; Watanabe T; Taguchi T; Tsukamoto F; Noguchi S
Gan To Kagaku Ryoho; 2000 Feb; 27(2):245-9. PubMed ID: 10700895
[TBL] [Abstract][Full Text] [Related]
57. Metformin may protect nondiabetic breast cancer women from metastasis.
El-Haggar SM; El-Shitany NA; Mostafa MF; El-Bassiouny NA
Clin Exp Metastasis; 2016 Apr; 33(4):339-57. PubMed ID: 26902691
[TBL] [Abstract][Full Text] [Related]
58. Possible effects of insulin-like growth factor-I, IGF-binding protein-3 and IGF-1/IGFBP-3 molar ratio on mammographic density: a cross-sectional study.
Meggiorini ML; Cipolla V; Borgoni G; Nofroni I; Pala A; de Felice C
Eur J Gynaecol Oncol; 2012; 33(1):74-8. PubMed ID: 22439410
[TBL] [Abstract][Full Text] [Related]
59. Does raloxifene reduce postmenopausal women's risk of breast cancer?
Han RK; Pimlott N; Heisey R
Can Fam Physician; 2000 Jan; 46():77-80. PubMed ID: 10660790
[No Abstract] [Full Text] [Related]
60. Toremifene citrate (Fareston).
Gerken P
Clin J Oncol Nurs; 2004 Oct; 8(5):529-30. PubMed ID: 15565747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
